Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Study

Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer.

Mohamed MR, Mohile SG, Juba KM, et al. Association of polypharmacy and potential drug‐drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer. 2023;129(7):1096-1104. doi:10.1002/cncr.34642.

Save
Print
July 19, 2023
Mohamed MR, Mohile SG, Juba KM, et al. Cancer. 2023;129(7):1096-1104.
View more articles from the same authors.

Polypharmacy in older adults increases the risk of potentially inappropriate medications (PIM) and potential drug-drug interactions (PDI). This secondary analysis of a national study of older adults with advanced cancer sought to identify associations between polypharmacy (eight or more medications), PIMs, and PDIs with adverse cancer treatment outcomes. Polypharmacy and PDIs were associated with increased risk of adverse treatment outcomes, but PIMs were not.

Save
Print
Cite
Citation

Mohamed MR, Mohile SG, Juba KM, et al. Association of polypharmacy and potential drug‐drug interactions with adverse treatment outcomes in older adults with advanced cancer. Cancer. 2023;129(7):1096-1104. doi:10.1002/cncr.34642.